News

In recent years, the arrival of novel hemophilia treatments that are effective and less burdensome to administer have opened up new possibilities…

Takeda today announced that it is conducting a voluntary market withdrawal for two product lots of 650 IU VONVENDI® [von Willebrand factor]…

Roctavian™ was approved in the summer of 2023 for the treatment of adults with severe hemophilia. The first hemophilia A gene therapy…

Takeda announces a voluntary withdrawal for 650 IU VONVENDI® due to misprinted labels showing incorrect expiration dates. Takeda announced today that it…

Takeda announces a voluntary withdrawal for 650 IU VONVENDI® due to misprinted labels showing incorrect expiration dates. Takeda announced today that it…

Roctavian™ was approved in the summer of 2023 for the treatment of adults with severe hemophilia A The first hemophilia A gene…

GLHF is excited to celebrate 50 years of educating, supporting and advocating for the bleeding disorders community of Wisconsin. Since 1974, GLHF…

In recognition of the National Bleeding Disorders Foundation’s 75th anniversary, the Nursing Working Group gathered recorded video interviews of established nurses working…

Learn why women, girls, and people with the potential to menstruate (WGPPM) who have hemophilia, von Willebrand disease, or other inheritable blood…

Researchers at the Yale School of Medicine have been studying the key clotting protein von Willebrand factor (VWF), to shed light on…

Hemophilia Federation of America (HFA) and the National Bleeding Disorders Foundation (NBDF) are deeply concerned by the World Health Organization’s (WHO) recommendation…

Women who have von Willebrand disease or hemophilia are not at risk for other female medical problems, but two common disorders in…

Though it is generally recognized in the bleeding disorders community that physical therapists (PTs) are essential members of the core interdisciplinary teams…

Fun Facts About a von Willebrand Warrior is a new softcover storybook for children with von Willebrand disease that empowers and educates…

With the advent of gene therapy, patients will need to educate themselves more about eligibility, risks, compliance and costs. And they should educate…

Women with bleeding disorders and other medical concerns, or who have von Willebrand disease or hemophilia, are not necessarily at risk for…

Findings of a new study uncovered specific disparities in hemophilia care by focusing on the use of immune tolerance therapy (ITI) in…

November was Transgender Health Awareness Month, a time to reflect on the experiences of transgender and gender nonconforming individuals seeking and receiving…

The first patient has been dosed in ASC Therapeutics clinical trial of ASC618, the company’s investigational AAV8 vector-based gene therapy for patients…

Tickets on sale December 18!  Holiday-priced tickets for Milwaukee’s, Madison’s and Green Bay’s Best Bloody will be on sale Dec. 18 – Jan….

In this video, Dr. Radek Kaczmarek of the Indiana University School of Medicine lays out the scientific advances underpinning two currently approved gene…

While bloodletting was abandoned long ago by modern medicine, the procedure is still used today to treat specific medical conditions. Phlebotomy —…

Here’s why people with bleeding disorders need to know about it. Have you heard of metabolic dysfunction-associated steatotic liver disease, or MASLD?…

Did you know that GLHF serves as the Regional Core Center of Region V-West/Northern States Region for the United States Hemophilia Treatment…